Happy Mother's Day! Taking A Look Ahead Watching and

New Post Public Reply Private Reply Replies (3) Message Board
MGK_2
674
Happy Mother's Day!

Taking A Look Ahead

Watching and waiting. Not just waiting, but also watching and stating what I see. Others too, who watch, as do I can see where we are headed.

Nader was put out, like unto death but not unto death. He had not been able to further himself regardless of the weapon he wielded. He had an inability to fight his foes. He was therefore shut down.

Early celebrations turned dark. The thinking that winning was imminent was hit with RTF and warning letters. Yet, Nader was right on both accounts and they pull ahead on their lies and deception.

Nader escapes by termination. His way out. CytoDyn's way out. Nader's steep monetary draw now eliminated. CytoDyn operates down to the bare minimum. Efficiency rules. We no longer barrel down head long the road with a megaphone announcing every detail and every play. Even the most prized and pertinent details are put away to be appropriately announced at strategic moments. However, what our enemies do not realize remains the same fact that the same power which Nader constantly orated and proclaimed about is the same power which will level them and it grows mightier by the day.

Things are not as it they may appear. Too many would love you to believe that CytoDyn is in dire straights. I believe CytoDyn will say something small about NASH 700 pretty soon. We already know that this will happen in mid-June, but I think we will get something prior to that. It doesn't have to be a complete revelation. It can be partial. Just need to keep them off our backs. We need them to have a taste of the bomb blast that's coming. Just give us a taste CytoDyn, we don't need to eat.

On Amarex, I stand by what I said yesterday. We won't negotiate. There is much behind the BLA they submitted to the FDA on our behalf for the HIV indication. There are perpetrators and big money as well as big pharma behind this act of maleficence. None are immune. All have deep pockets. All will be found out and discovered. The implications of which are enormous. CytoDyn swallows whole the elephant in the room. Negotiations? There will be nothing left to negotiate for, not even half an ear. No crumbs under the table. And Amarex will not be the only one consumed.

It seems like the waters are calm for big pharma's ship. It's smooth sailing right now. All they need to do is to continue to pay interest on the borrowed short shares and they will succeed on keeping the lid on leronlimab. Just, maintain at least the 50 million short shares, keeping the cork in the bottle and keep adding even more than 80% of daily trades as short. Do what ever it takes to keep this thing from blowing, even when the bottle is shaken, when the world wants in, and certainly, do what ever has to be done to keep this pressure cooker down. Therefore do it, they command to their brokers, short it, as long as the word Leronlimab is kept at bay.

CytoDyn shall speak and the bottle shakes. CytoDyn already know what they will say. That time soon approaches.

Sidley Austin shall speak. Their time comes, and is beyond the horizon.

Either one of these or the culmination of the two, but I think it will be sudden rather than a slow upward drip. A sudden spoken word, apt & apropos, brings on the sudden collapse of this tall stack of short suppressive shares and the elimination of any attack and the evaporation of the worst of them as CytoDyn will have engorged itself in their plunder.

That's my conclusion when it comes to Amarex and NASH.

//

Now onto partnerships.

Just to remind you all. I speak with confidence because we own Leronlimab. I have no other reason to be confident other than solely on account of our asset. I take my forwardness because of that drug.

Unless Amarex concludes rapidly and we are awarded a massive windfall, (which I do not perceive happening all that soon, but I know it will come), CytoDyn needs to partner. CytoDyn needs to remain in control of all the partnerships it engages into. The partner needs to understand that it is their privilege to partner with CytoDyn, because Leronlimab causes their drug to be successful. CytoDyn must maintain ownership of the molecule. All partnerships terminate once their drug goes generic. After that, doctors may prescribe their drug alone, Leronlimab alone or still the combination of the drug/the generic with Leronlimab.

Partnerships are the only way, without a massive windfall, to go forward. And that is why I think we need a CEO who already has experience with many big pharmaceuticals and who is respected by them. and who has pertinent contacts with them or he may know many of the pharmaceutical suppliers and supporters and be well credentialed. It will be through this person, that CytoDyn develops into a Big Pharma itself and within his tenure, that CytoDyn greatly expands and morphs into adulthood.

Obstacles? Road blocks? Detours? No. There won't be any.

Everyone will want to be paired up with Leronlimab and that is our opportunity to expand our indication list. Big Pharma's mantra will be, "If you can't beat 'em, join 'em." If you can't beat Leronlimab, then partner with it. CytoDyn decisively takes market share. Shorts will have found greener pastures for months and months already.

CytoDyn needs to remain vigilant. Be careful of the covenants you sign CytoDyn. Leronlimab may not be breached. That must be forbidden. There can be no access to its assembly or manufacturing. There can be no understanding to its formula. There can be no decoding.

If for whatever reason, this is actually breached. all contracts / partnerships cease at once and CytoDyn goes it alone again. That must be written in every contract. Whoever would have breached this will be fighting with their best foot forward to again destroy CytoDyn.



Hope we hear from CytoDyn shortly.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurzen Leverages Basquiat for Art-Infused Projection Line

Updated Category News Views 2

A Fresh Perspective on Portable Projection If anyone had told me a tech brand would buddy up with the world of fine art to launch a new gadget line, I'd have raised an eyebrow. But here we are, shrugging away the standard and looking at what's cooking over at Aurzen. The company's new initiative, 'Unfold the Art,' marries the magnetism of Jean-Michel Basquiat's artwork...

Continue Reading
PinkBlush Maternity Unveils Its 2026 Fall Fashion Line

Updated Category News Views 2

Elevating Maternity Fashion with PinkBlush's Fall 2026 Line You know, it's not every day you see maternitywear aiming to push the envelope, but that's exactly what PinkBlush is doing this fall. They've unleashed their Fall 2026 collection, and let's just say, it's less about the frills and more about redefining what expecting mothers can expect from the fashion world. A...

Continue Reading
Lennar Unveils Lake Martin Community Homes

Updated Category News Views 3

Lake Martin's New Residential Offering Step aside, beaches and mountains. Now it's all about lakeside living with some good old Alabama charm. Lennar, a heavyweight in the homebuilding scene, is opening the gates to The Oaks at Eclectic—a fresh batch of single-family homes sprouting near Lake Martin in Eclectic, Alabama. This spot is practically a haven for those who...

Continue Reading
Lupin Gains FDA Nod for Modafinil, Eyes US Market

Updated Category News Views 1

In the ever-evolving landscape of pharmaceuticals, Lupin Limited's recent triumph snagging FDA approval for their Modafinil Tablets was a move you couldn't miss even if you'd tried. While the rooms of Mumbai and boardrooms around the globe might have been abuzz, investors should tune in to the humming potential of this development—especially if they're navigating the...

Continue Reading
AI Data Retention: FastGPT’s Detailed Deletion Protocols

Updated Category News Views 3

In the world of AI-driven applications, data retention has become a hot potato, especially when we're talking about sensitive information like conversation records and audit logs. FastGPT, an open-source AI platform, has decided to tell it like it is by detailing exactly how these data pieces are retained and ultimately booted out. All this info was scattered to the winds...

Continue Reading
CreditRefresh's AI Tackles 1,000+ Disputes Launch Month

Updated Category News Views 3

AI-Powered Revolution in Credit Disputes Alright, here we are staring down the latest twist in the credit game. CreditRefresh, an AI-driven platform out of Dover, Delaware, has managed to kickstart its journey by challenging over 1,000 credit report errors in just its first month on the market. That's quite a sprint straight from the gate, don't you think? But hey, this...

Continue Reading
TriStar Bank Community Room: A Space for Growth

Updated Category News Views 1

Building Bridges Through Community Investment Well, ain't this something? Columbia, Tennessee, just got a splash of fresh air. We're talking about the new Southern Regional Technology Center nested in Columbia State Community College. Now, the name on everyone's lips? The TriStar Bank Community Room. But it ain't just about a name plastered up on a wall inside a shiny...

Continue Reading
Fujifilm's New 400mm Lens: A Game Changer?

Updated Category News Views 1

Big Moves from Fujifilm's Camp Now we're talking, Fujifilm! Just when you think they might ease off the throttle, they crank up the heat with the XF 400mm f/4.5 R LM OIS WR lens. This isn’t just your run-of-the-mill update. It's a significant addition to their already beefed-up lineup for sports and wildlife. You know what that means: more reach, less baggage. Compact...

Continue Reading
New Concierge Pediatric Care at Weill Cornell Launches

Updated Category News Views 1

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Continue Reading
Inturai Ventures Closes Final Tranche with a Twist

Updated Category News Views 2

Wrapping Up a Wild Ride in the Investment Arena Markets are a fickle friend, and today we've got Inturai Ventures calling it a day on their latest cash grab. They've locked the final tranche of their private placement, pulling in an aggregate $963,713.70. Feels like they're counting pennies in this venture, but every cent counts when your aim is to shake up industries...

Continue Reading

Top 5 Most Recently Viewed Articles

Canadian Life Companies Split Corp. Announces Share Dividend

Updated Category News Views 121

Canadian Life Companies Split Corp. Dividend Announcement Canadian Life Companies Split Corp. is excited to announce the declaration of its monthly dividend distributions. For each Class A share, the corporation will distribute $0.10000, and for each Preferred share, a distribution of $0.05833 has been set. These distributions will be payable on November 10, 2025, to...

Continue Reading
Quantum Corp. Class Action Lawsuit: What Investors Need to Know

Updated Category News Views 185

Understanding the Quantum Corp. Lawsuit Recently, a class action lawsuit was initiated against Quantum Corporation, also known as Quantum Corp. This development stems from accusations regarding the company's financial reporting practices. The lawsuit suggests that the company may have incorrectly accounted for its revenue during the financial period that concluded in...

Continue Reading
Capricor Therapeutics: Key Deadlines for Shareholders to Remember

Updated Category News Views 129

Crucial Dates for Capricor Therapeutics Shareholders The Gross Law Firm has released an important notice for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm encourages anyone who purchased shares during the specified class period to connect with them regarding possible lead plaintiff appointments. Being appointed as the lead plaintiff isn't necessary...

Continue Reading
Voting Rights Update: Key Figures and Company Overview

Updated Category News Views 110

Understanding KBC Ancora's Voting Rights KBC Ancora periodically updates its shareholders on the total number of voting rights associated with its shares. As part of its compliance with the regulatory framework, specifically the Article 15 of the Act of 2 May 2007, KBC Ancora shares information about its capital, voting shares, and rights that might influence shareholder...

Continue Reading
Brenmiller Energy's Thermal Storage Boosts Clean Energy in Spain

Updated Category News Views 105

Brenmiller Energy's Innovative Partnership for a Greener Future Brenmiller Energy Ltd. (Nasdaq: BNRG) has made a significant stride in the world of clean energy with the announcement of their bGen™ ZERO thermal energy storage system being selected for an ambitious project led by Resources of Biomass (REBI), a prominent Energy Service Company in Spain. This collaboration...

Continue Reading